Cargando…

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers

PURPOSE: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such treatment. PATIENTS AND METHODS: In the NeoAva phase II clinical trial, patients (N = 132) with large (≥ 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haugen, Mads H., Lingjærde, Ole Christian, Hedenfalk, Ingrid, Garred, Øystein, Borgen, Elin, Loman, Niklas, Hatschek, Thomas, Børresen-Dale, Anne-Lise, Naume, Bjørn, Mills, Gordon B., Mælandsmo, Gunhild M., Engebraaten, Olav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2021
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140811/ https://www.ncbi.nlm.nih.gov/pubmed/34036235 http://dx.doi.org/10.1200/PO.20.00086

Ejemplares similares

Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
por: Krüger, Kristi, et al.
Publicado: (2021)

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
por: Lindholm, Evita Maria, et al.
Publicado: (2019)

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
por: Höglander, Elen Kristine, et al.
Publicado: (2018)

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
por: Normann, Lisa Svartdal, et al.
Publicado: (2023)

Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
por: Kimbung, Siker, et al.
Publicado: (2017)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
por: Engesæter, Birgit, et al.
Publicado: (2012)

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
por: Moestue, Siver A, et al.
Publicado: (2010)

RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
por: Engebraaten, Olav, et al.
Publicado: (2021)

miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
por: Normann, Lisa Svartdal, et al.
Publicado: (2022)

Basal‐like breast cancer engages tumor‐supportive macrophages via secreted factors induced by extracellular S100A4
por: Prasmickaite, Lina, et al.
Publicado: (2018)

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
por: Lien, Tonje G., et al.
Publicado: (2021)

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
por: Normann, Lisa Svartdal, et al.
Publicado: (2021)

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
por: Nygaard, Vigdis, et al.
Publicado: (2023)

Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
por: Grinde, Maria T, et al.
Publicado: (2014)

Differential In Vivo Tumorigenicity of Distinct Subpopulations from a Luminal-Like Breast Cancer Xenograft
por: Skrbo, Nirma, et al.
Publicado: (2014)

Liver X receptors induce antiproliferative effects in basal‐like breast cancer
por: Haugen, Mads Haugland, et al.
Publicado: (2023)

Cystatin E/M suppresses legumain activity and invasion of human melanoma
por: Briggs, Jon J, et al.
Publicado: (2010)

LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer
por: Sas‐Chen, Aldema, et al.
Publicado: (2016)

Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
por: Tamhane, Tripti, et al.
Publicado: (2015)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Nuclear Legumain Activity in Colorectal Cancer
por: Haugen, Mads H., et al.
Publicado: (2013)

Correction: Nuclear Legumain Activity in Colorectal Cancer
por: Haugen, Mads H., et al.
Publicado: (2013)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
por: Maelandsmo, G. M., et al.
Publicado: (1996)

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
por: Engebraaten, Olav, et al.
Publicado: (2012)

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
por: Silwal-Pandit, Laxmi, et al.
Publicado: (2015)

Breast cancer quantitative proteome and proteogenomic landscape
por: Johansson, Henrik J., et al.
Publicado: (2019)

Sensitization of interferon-γ induced apoptosis in human osteosarcoma cells by extracellular S100A4
por: Pedersen, Kjetil Boye, et al.
Publicado: (2004)

Combining Gene Signatures Improves Prediction of Breast Cancer Survival
por: Zhao, Xi, et al.
Publicado: (2011)

Serum N‐glycome alterations in breast cancer during multimodal treatment and follow‐up
por: Saldova, Radka, et al.
Publicado: (2017)

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
por: Rye, Inga H., et al.
Publicado: (2018)

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
por: Seip, Kotryna, et al.
Publicado: (2016)

Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
por: Øverbye, Anders, et al.
Publicado: (2017)

Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
por: Jabeen, Shakila, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
por: Fangberget, A., et al.
Publicado: (2010)

Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen
por: Barkovskaya, Anna, et al.
Publicado: (2021)

Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
por: Haukaas, Tonje H., et al.
Publicado: (2016)

Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
por: Tinholt, Mari, et al.
Publicado: (2020)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_110omenvl0rb132hblqoav295h